REGENXBIO Stock Forecast, Price & News

-0.09 (-0.24 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume128,372 shs
Average Volume275,451 shs
Market Capitalization$1.60 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.



REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.69 out of 5 stars

Medical Sector

338th out of 2,099 stocks

Biological Products, Except Diagnostic Industry

44th out of 198 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

REGENXBIO (NASDAQ:RGNX) Frequently Asked Questions

Is REGENXBIO a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last twelve months. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" REGENXBIO stock.
View analyst ratings for REGENXBIO
or view top-rated stocks.

What stocks does MarketBeat like better than REGENXBIO?

Wall Street analysts have given REGENXBIO a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but REGENXBIO wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is REGENXBIO's next earnings date?

REGENXBIO is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for REGENXBIO

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) announced its earnings results on Wednesday, May, 5th. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by $0.07. REGENXBIO had a negative trailing twelve-month return on equity of 27.80% and a negative net margin of 77.89%.
View REGENXBIO's earnings history

How has REGENXBIO's stock price been impacted by COVID-19 (Coronavirus)?

REGENXBIO's stock was trading at $32.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RGNX stock has increased by 14.6% and is now trading at $37.68.
View which stocks have been most impacted by COVID-19

What price target have analysts set for RGNX?

8 analysts have issued twelve-month price objectives for REGENXBIO's stock. Their forecasts range from $37.00 to $95.00. On average, they expect REGENXBIO's share price to reach $62.50 in the next year. This suggests a possible upside of 65.9% from the stock's current price.
View analysts' price targets for REGENXBIO
or view top-rated stocks among Wall Street analysts.

Who are REGENXBIO's key executives?

REGENXBIO's management team includes the following people:
  • Mr. Kenneth T. Mills, Pres, CEO & Director (Age 46, Pay $997.83k)
  • Mr. Vittal K. Vasista, Sr. VP & CFO (Age 53, Pay $650.85k)
  • Mr. Curran M. Simpson M.S., Sr. VP and Chief Operations & Technology Officer (Age 59, Pay $618.54k)
  • Dr. Olivier Danos, Sr. VP & Chief Scientific Officer (Age 63, Pay $623.86k)
  • Mr. Patrick J. Christmas II, Sr. VP & Chief Legal Officer (Age 50, Pay $613.14k)
  • Ms. Tricia Truehart, VP of Investor Relations & Corp. Communications
  • Mr. Andrew Yost, VP of Corp. Devel.
  • Ms. Shiva G. Fritsch, Chief People Officer
  • Dr. Laura A. Coruzzi, Sr. VP of Intellectual Property (Age 68)
  • Mr. Ram Palanki, Sr. VP of Commercial Strategy & Operations

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO CEO Ken Mills on Ken Mills has an approval rating of 68% among REGENXBIO's employees.

Who are some of REGENXBIO's key competitors?

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Square (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.83%), JPMorgan Chase & Co. (8.24%), Redmile Group LLC (5.51%), Point72 Asset Management L.P. (2.13%), Dimensional Fund Advisors LP (1.95%) and Geode Capital Management LLC (1.48%). Company insiders that own REGENXBIO stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Patrick J Christmas and Vittal Vasista.
View institutional ownership trends for REGENXBIO

Which major investors are selling REGENXBIO stock?

RGNX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., BNP Paribas Arbitrage SA, Botty Investors LLC, Man Group plc, State of New Jersey Common Pension Fund D, First Manhattan Co., Korea Investment CORP, and Credit Suisse AG. Company insiders that have sold REGENXBIO company stock in the last year include Curran Simpson, Kenneth T Mills, Patrick J Christmas, and Vittal Vasista.
View insider buying and selling activity for REGENXBIO
or view top insider-selling stocks.

Which major investors are buying REGENXBIO stock?

RGNX stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BlackRock Inc., Point72 Asset Management L.P., Redmile Group LLC, Millennium Management LLC, Dimensional Fund Advisors LP, RTW Investments LP, and D. E. Shaw & Co. Inc..
View insider buying and selling activity for REGENXBIO
or or view top insider-buying stocks.

How do I buy shares of REGENXBIO?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $37.68.

How much money does REGENXBIO make?

REGENXBIO has a market capitalization of $1.60 billion and generates $154.57 million in revenue each year. The biotechnology company earns $-111,250,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis.

How many employees does REGENXBIO have?

REGENXBIO employs 306 workers across the globe.

What is REGENXBIO's official website?

The official website for REGENXBIO is

Where are REGENXBIO's headquarters?

REGENXBIO is headquartered at 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at (240) 552-8181 or via email at [email protected]

This page was last updated on 6/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.